The study indicates that abnormal overexpression of PCSK9 enhances cell proliferation and confers resistance to sorafenib in hepatocellular carcinoma by facilitating AKT-S473 phosphorylation (131). Here, AKT1 is linked to hepatocellular carcinoma.